Osaic Holdings
SPRB

Osaic Holdings’s Spruce Biosciences SPRB Stock Holding History

Osaic Holdings’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-133
Closed -$931 – 8300
2025
Q3 		$931 Buy
+133
New +$1.18K ﹤0.01% 7382

Other funds holding SPRB

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return

Osaic Holdings's SPRB Position: Q4 2025 in Review

Osaic Holdings sold out of Spruce Biosciences (SPRB) in Q4 2025, closing a stake of 133 shares — an estimated $931 sold.

Osaic Holdings first reported a position in SPRB in Q3 2025 and held it in 1 quarter. The position peaked at $931 in Q3 2025. 32 funds tracked by Wall St. Rank hold SPRB as of Q4 2025.

  • Osaic Holdings reported no remaining Spruce Biosciences position as of Q4 2025 after selling out during the quarter.
  • Osaic Holdings sold 133 Spruce Biosciences shares in Q4 2025, an estimated $931.
  • Osaic Holdings first reported a position in Spruce Biosciences in Q3 2025 and held it in 1 quarter.
  • Osaic Holdings's Spruce Biosciences position peaked at $931 in Q3 2025.
  • 32 funds tracked by Wall St. Rank held Spruce Biosciences as of Q4 2025.

Based on Osaic Holdings's 13F filing for Q4 2025, filed 17 Feb 2026.